Long-Term Treatment with Eldecalcitol (1α, 25-Dihydroxy-2β- (3-hydroxypropyloxy) Vitamin D3) Suppresses Bone Turnover and Leads to Prevention of Bone Loss and Bone Fragility in Ovariectomized Rats